MTOR and neutropenia: A meta-analysis of published reports on 5436 patients treated with mTOR inhibitors showed a nonsignificantly increased risk of all-grade leukopenia and neutropenia [158], while another meta-analysis of 3180 mTOR inhibitor-treated patients [159] demonstrated a relative risk of all-grade and high-grade infections of 2.00 (95% CI, 1.76−2.28, p < 0.001) and 2.60 (95% CI, 1.54−4.41, p < 0.001), respectively, as compared with patients in the control arms of the studies.